BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 16600352)

  • 1. A meta-analysis of the performance characteristics of the free prostate-specific antigen test.
    Lee R; Localio AR; Armstrong K; Malkowicz SB; Schwartz JS;
    Urology; 2006 Apr; 67(4):762-8. PubMed ID: 16600352
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The ratio of prostate-specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL.
    Stephan C; Stroebel G; Heinau M; Lenz A; Roemer A; Lein M; Schnorr D; Loening SA; Jung K
    Cancer; 2005 Sep; 104(5):993-1003. PubMed ID: 16007682
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer.
    Brawer MK; Cheli CD; Neaman IE; Goldblatt J; Smith C; Schwartz MK; Bruzek DJ; Morris DL; Sokoll LJ; Chan DW; Yeung KK; Partin AW; Allard WJ
    J Urol; 2000 May; 163(5):1476-80. PubMed ID: 10751861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of several combinations of free, complexed, and total PSA in the diagnosis of prostate cancer in patients with urologic symptoms.
    Filella X; Truan D; Alcover J; Quintó L; Molina R; Luque P; Coca F; Ballesta AM
    Urology; 2004 Jun; 63(6):1100-3; discussion 1103-4. PubMed ID: 15183958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of proprostate specific antigen for early detection of prostate cancer in men with a total prostate specific antigen range of 4.0 to 10.0 ng/ml.
    Khan MA; Partin AW; Rittenhouse HG; Mikolajczyk SD; Sokoll LJ; Chan DW; Veltri RW
    J Urol; 2003 Sep; 170(3):723-6. PubMed ID: 12913682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prostate-specific antigen and free prostate-specific antigen in the early detection of prostate cancer: do combination tests improve detection?
    Etzioni R; Falcon S; Gann PH; Kooperberg CL; Penson DF; Stampfer MJ
    Cancer Epidemiol Biomarkers Prev; 2004 Oct; 13(10):1640-5. PubMed ID: 15466981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative evaluation of various prostate specific antigen ratios for the early detection of prostate cancer.
    Ozdal OL; Aprikian AG; Bégin LR; Behlouli H; Tanguay S
    BJU Int; 2004 May; 93(7):970-4; discussion 974. PubMed ID: 15142145
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complexed prostate specific antigen density is better than the other PSA derivatives for detection of prostate cancer in men with total PSA between 2.5 and 20 ng/ml: results of a prospective multicenter study.
    Sözen S; Eskicorapci S; Küpeli B; Irkilata L; Altinel M; Ozer G; Uygur C; Alkibay T; Ozen H
    Eur Urol; 2005 Mar; 47(3):302-7. PubMed ID: 15716190
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PSA-related markers in the detection of prostate cancer and high-grade disease in the contemporary era with extended biopsy.
    Bratslavsky G; Fisher HA; Kaufman RP; Voskoboynik D; Nazeer T; Mian BM
    Urol Oncol; 2008; 26(2):166-70. PubMed ID: 18312936
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Electrophoretic subforms of free prostate-specific antigen in serum as promising diagnostic tool in prostate cancer diagnostics.
    Jung K; Hoesel W; Reiche J; Deger S; Kramer J; Loening SA; Lein M; Stephan C
    Urology; 2007 Feb; 69(2):320-5. PubMed ID: 17320672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen.
    Punglia RS; D'Amico AV; Catalona WJ; Roehl KA; Kuntz KM
    N Engl J Med; 2003 Jul; 349(4):335-42. PubMed ID: 12878740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network.
    Stephan C; Cammann H; Deger S; Schrader M; Meyer HA; Miller K; Lein M; Jung K
    Urology; 2009 Oct; 74(4):873-7. PubMed ID: 19476981
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Different prostate-specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies.
    Stephan C; Kramer J; Meyer HA; Kristiansen G; Ziemer S; Deger S; Lein M; Loening SA; Jung K
    BJU Int; 2007 Jun; 99(6):1427-31. PubMed ID: 17355366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Using multiple cutpoints for the free-to-total prostate specific antigen ratio improves the accuracy of prostate cancer detection.
    Hoffman RM; Clanon DL; Chavez M; Peirce JC
    Prostate; 2002 Jul; 52(2):150-8. PubMed ID: 12111706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of systematic 12-core biopsy on the performance of percent free prostate specific antigen for prostate cancer detection.
    Canto EI; Singh H; Shariat SF; Kadmon D; Miles BJ; Wheeler TM; Slawin KM
    J Urol; 2004 Sep; 172(3):900-4. PubMed ID: 15310993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
    Raaijmakers R; de Vries SH; Blijenberg BG; Wildhagen MF; Postma R; Bangma CH; Darte C; Schröder FH
    Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of the relative probability for prostate cancer to avoid unnecessary biopsy.
    Okamura K; Takaba H; Kamihira O; Kinukawa T; Ono Y; Ohshima S; Nagasaka T
    Int J Urol; 2005 Apr; 12(4):346-52. PubMed ID: 15948720
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical utility of proPSA and "benign" PSA when percent free PSA is less than 15%.
    Khan MA; Sokoll LJ; Chan DW; Mangold LA; Mohr P; Mikolajczyk SD; Linton HJ; Evans CL; Rittenhouse HG; Partin AW
    Urology; 2004 Dec; 64(6):1160-4. PubMed ID: 15596190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection.
    Stephan C; Jung K; Soosaipillai A; Yousef GM; Cammann H; Meyer H; Xu C; Diamandis EP
    BJU Int; 2005 Sep; 96(4):521-7. PubMed ID: 16104903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A (-5, -7) proPSA based artificial neural network to detect prostate cancer.
    Stephan C; Meyer HA; Kwiatkowski M; Recker F; Cammann H; Loening SA; Jung K; Lein M
    Eur Urol; 2006 Nov; 50(5):1014-20. PubMed ID: 16697520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.